JP2019536818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536818A5 JP2019536818A5 JP2019548783A JP2019548783A JP2019536818A5 JP 2019536818 A5 JP2019536818 A5 JP 2019536818A5 JP 2019548783 A JP2019548783 A JP 2019548783A JP 2019548783 A JP2019548783 A JP 2019548783A JP 2019536818 A5 JP2019536818 A5 JP 2019536818A5
- Authority
- JP
- Japan
- Prior art keywords
- myopathy
- muscle
- disease
- loss
- atrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083666A JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1620119.6 | 2016-11-29 | ||
| GBGB1620119.6A GB201620119D0 (en) | 2016-11-29 | 2016-11-29 | Compounds |
| PCT/IB2017/057436 WO2018100483A1 (en) | 2016-11-29 | 2017-11-28 | Muscle performance improvement compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083666A Division JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536818A JP2019536818A (ja) | 2019-12-19 |
| JP2019536818A5 true JP2019536818A5 (cg-RX-API-DMAC7.html) | 2021-01-14 |
| JP7683901B2 JP7683901B2 (ja) | 2025-05-27 |
Family
ID=58073474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548783A Active JP7683901B2 (ja) | 2016-11-29 | 2017-11-28 | 筋肉性能改善化合物 |
| JP2023083666A Pending JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083666A Pending JP2023116479A (ja) | 2016-11-29 | 2023-05-22 | 筋肉性能改善化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11407799B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3548509A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7683901B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102622245B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110036024B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017367277B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3045245A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201620119D0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ754625A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018100483A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201903261B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
| KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN120535607A (zh) | 2018-01-12 | 2025-08-26 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP2023512423A (ja) * | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| EP4121090A4 (en) * | 2020-03-20 | 2024-09-04 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4185316A4 (en) * | 2020-07-24 | 2024-07-17 | Agency for Science, Technology and Research | WOUND HEALING COMPOSITION AND USES THEREOF |
| BR112023018283A2 (pt) * | 2021-03-10 | 2023-10-31 | Acceleron Pharma Inc | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca |
| KR20230169123A (ko) * | 2021-03-10 | 2023-12-15 | 악셀레론 파마 인코포레이티드 | Actrii-alk4 길항제 및 심부전을 치료하는 방법 |
| CN117999278A (zh) | 2021-06-21 | 2024-05-07 | 裘美娜治疗公司 | 再生性多肽及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09503673A (ja) * | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| US20060216279A1 (en) * | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| EP2056850A4 (en) | 2006-08-08 | 2011-10-12 | Univ Louisiana State | THERAPEUTIC PROCEDURES FOR NEUROPATHIC PAIN |
| BRPI0716249A2 (pt) * | 2006-09-05 | 2013-09-03 | Lilly Co Eli | anticorpos antimiostatina |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| HUE035240T2 (hu) * | 2009-04-27 | 2018-05-02 | Novartis Ag | Készítmények és eljárások az izomerõ növelésére |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| EP2295068A1 (en) * | 2009-09-04 | 2011-03-16 | Neurotune AG | Modified agrin-fragment capable of restoring muscle strength for use as a medicament |
| US8710016B2 (en) * | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
-
2016
- 2016-11-29 GB GBGB1620119.6A patent/GB201620119D0/en not_active Ceased
-
2017
- 2017-11-28 US US16/464,969 patent/US11407799B2/en active Active
- 2017-11-28 CN CN201780073720.2A patent/CN110036024B/zh active Active
- 2017-11-28 WO PCT/IB2017/057436 patent/WO2018100483A1/en not_active Ceased
- 2017-11-28 CA CA3045245A patent/CA3045245A1/en active Pending
- 2017-11-28 NZ NZ754625A patent/NZ754625A/en unknown
- 2017-11-28 JP JP2019548783A patent/JP7683901B2/ja active Active
- 2017-11-28 AU AU2017367277A patent/AU2017367277B2/en active Active
- 2017-11-28 EP EP17808609.6A patent/EP3548509A1/en active Pending
- 2017-11-28 KR KR1020197018624A patent/KR102622245B1/ko active Active
-
2019
- 2019-05-23 ZA ZA2019/03261A patent/ZA201903261B/en unknown
-
2023
- 2023-05-22 JP JP2023083666A patent/JP2023116479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536818A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535675A5 (cg-RX-API-DMAC7.html) | ||
| Braun et al. | Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells | |
| Abu-Shakra et al. | Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies | |
| JP2012070739A5 (cg-RX-API-DMAC7.html) | ||
| Flesch et al. | Nonacidic farnesoid X receptor modulators | |
| TWI826358B (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合ａｃｔｒｉｉｂ配體陷阱蛋白及其用途與生產方法 | |
| JP2014158480A5 (cg-RX-API-DMAC7.html) | ||
| Poggiogalle et al. | Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects | |
| US8309525B2 (en) | Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof | |
| BR122020006907B1 (pt) | Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| JP2017019804A (ja) | ペプチド模倣大環状分子 | |
| RU2017138537A (ru) | Новые гибридные ActRIIB белки-ловушки лигандов для лечения заболеваний, связанных с мышечной атрофией | |
| JP2015091868A5 (cg-RX-API-DMAC7.html) | ||
| JP2006517581A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533889A (ja) | ペプチド模倣大環状分子およびその使用 | |
| JP2014502141A5 (cg-RX-API-DMAC7.html) | ||
| TW201000467A (en) | Novel 1,2,4-triazole derivatives and process of manufacturing thereof | |
| JP2022542016A (ja) | ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法 | |
| US20140004136A1 (en) | Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies | |
| Islam et al. | Incorporation of α-methylated amino acids into Apolipoprotein AI mimetic peptides improves their helicity and cholesterol efflux potential | |
| Reilich et al. | A novel mutation in the myotilin gene (MYOT) causes a severe form of limb girdle muscular dystrophy 1A (LGMD1A) | |
| Li et al. | Basic biology and roles of CEBPD in cardiovascular disease | |
| Sahlholm et al. | Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice | |
| Dodson et al. | Crystal structure, aggregation and biological potency of beef insulin cross-linked at A1 and B29 by diaminosuberic acid |